Erratum: Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition (Proceedings of the National Academy of Sciences of the United States of America (2013) 110:48 (19426-19431) DOI: 10.1073/pnas.1309473110);Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 48, 2013, Pages 19426-19431

  Kirkpatrick, Donald S ^a   Bustos, Daisy J ^a   Dogan, Taner ^a   Chan, Jocelyn ^a   Phu, Lilian ^a   Young, Amy ^a   Friedman, Lori S ^a   Belvin, Marcia ^a   Song, Qinghua ^a   Bakalarski, Corey E ^a   Hoeflich, Klaus P ^a  

^a GENENTECH INC   (United States)

Author keywords

Phosphoproteomics; PI3 kinase; PRKDC

Indexed keywords

ATM PROTEIN; COBIMETINIB; DNA DEPENDENT PROTEIN KINASE; GLUTAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; SERINE; THREONINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; IC 50; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEOMICS; RNA METABOLISM;

ATAXIA TELANGIECTASIA;

EID: 84888387045     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322630111     Document Type: Erratum

References (44)

1. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1): 11-22.
2. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8): 606-619.
3. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22): 3291-3310.
4. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4(12): 937-947.
5. Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/ Akt pathway in cancer. Oncogene 27(41): 5511-5526.
6. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8): 627-644.
7. Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286(5445): 1741-1744.
8. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81(2): 807-869.
9. Alessi DR, et al. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15(23): 6541-6551.
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712): 1098-1101.
11. Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23(1): 94-101.
12. Moritz A, et al. (2010) Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 3(136):ra64.
13. Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316(5828): 1160-1166.
14. Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci USA 104(50): 19855-19860.
15. Kim ST, Lim DS, Canman CE, Kastan MB (1999) Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274(53): 37538-37543.
16. Folkes AJ, et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51(18): 5522-5532.
17. Hoeflich KP, et al. (2012) Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72(1): 210-219.
18. Hoeflich KP, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15(14): 4649-4664.
19. Wallin JJ, et al. (2011) GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10(12): 2426-2436.
20. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8): 3041-3046.
21. Beausoleil SA, Villén J, Gerber SA, Rush J, Gygi SP (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24(10): 1285-1292.
22. Meek K, Dang V, Lees-Miller SP (2008) DNA-PK: The means to justify the ends? Adv Immunol 99: 33-58.
23. Ding Q, et al. (2003) Autophosphorylation of the catalytic subunit of the DNAdependent protein kinase is required for efficient end processing during DNA doublestrand break repair. Mol Cell Biol 23(16): 5836-5848.
24. Meek K, Douglas P, Cui X, Ding Q, Lees-Miller SP (2007) trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Mol Cell Biol 27(10): 3881-3890.
25. Bakalarski CE, et al. (2008) The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res 7(11): 4756-4765.
26. Clough T, et al. (2009) Protein quantification in label-free LC-MS experiments. J Proteome Res 8(11): 5275-5284.
27. Clough T, Thaminy S, Ragg S, Aebersold R, Vitek O (2012) Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics 13(Suppl 16):S6.
28. Liu S, et al. (2012) Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res 40(21): 10780-10794.
29. Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9(6): 1314-1323.
30. Bensimon A, et al. (2010) ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. Sci Signal 3(151):rs3.
31. Powis G, et al. (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol- 3-kinase. Cancer Res 54(9): 2419-2423.
32. Sarkaria JN, et al. (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58(19): 4375-4382.
33. Mukherjee B, et al. (2012) The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14(1): 34-43.
34. Kong D, Yaguchi S, Yamori T (2009) Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull 32(2): 297-300.
35. Ibrahim YH, et al. (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11): 1036-1047.
36. Juvekar A, et al. (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2(11): 1048-1063.
37. Bozulic L, Surucu B, Hynx D, Hemmings BA (2008) PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30(2): 203-213.
38. Mukherjee B, et al. (2006) DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst) 5(5): 575-590.
39. Tsai YC, Greco TM, Boonmee A, Miteva Y, Cristea IM (2012) Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics 11(5): 60-76.
40. Butter F, Scheibe M, Mörl M, MannM(2009) Unbiased RNA-protein interaction screen by quantitative proteomics. Proc Natl Acad Sci USA 106(26): 10626-10631.
41. Gorospe M, de Cabo R (2008) AsSIRTing the DNA damage response. Trends Cell Biol 18(2): 77-83.
42. Ma XM, Yoon SO, Richardson CJ, Jülich K, Blenis J (2008) SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 133(2): 303-313.
43. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT (2010) ATM activation by oxidative stress. Science 330(6003): 517-521.
44. Soutoglou E, Misteli T (2008) Activation of the cellular DNA damage response in the absence of DNA lesions. Science 320(5882): 1507-1510.